Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Income from Non-Controlling Interests: 2019-2024

Historic Income from Non-Controlling Interests for ImmunityBio (IBRX) over the last 6 years, with Dec 2024 value amounting to -$81,000.

  • ImmunityBio's Income from Non-Controlling Interests rose 8.70% to -$21,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$77,000, marking a year-over-year increase of 10.47%. This contributed to the annual value of -$81,000 for FY2024, which is 87.65% up from last year.
  • As of FY2024, ImmunityBio's Income from Non-Controlling Interests stood at -$81,000, which was up 87.65% from -$656,000 recorded in FY2023.
  • ImmunityBio's Income from Non-Controlling Interests' 5-year high stood at -$81,000 during FY2024, with a 5-year trough of -$3.1 million in FY2021.
  • In the last 3 years, ImmunityBio's Income from Non-Controlling Interests had a median value of -$656,000 in 2023 and averaged -$496,667.
  • As far as peak fluctuations go, ImmunityBio's Income from Non-Controlling Interests tumbled by 30.91% in 2021, and later surged by 87.65% in 2024.
  • Over the past 5 years, ImmunityBio's Income from Non-Controlling Interests (Yearly) stood at -$2.3 million in 2020, then plummeted by 30.91% to -$3.1 million in 2021, then surged by 75.38% to -$753,000 in 2022, then increased by 12.88% to -$656,000 in 2023, then soared by 87.65% to -$81,000 in 2024.